Status:
UNKNOWN
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer
Lead Sponsor:
Peking University People's Hospital
Conditions:
Breast Neoplasms
Magnetic Resonance Imaging
Eligibility:
FEMALE
Brief Summary
Use Convolutional Neural Networks Analysis for Classification of Contrast-enhancing Lesions at Multiparametric Breast MRI. Build an abbreviated protocal, and investigate whether an abbreviated protoco...
Eligibility Criteria
Inclusion
- Patients with clinical symptoms (define as palpable mass, nipple discharge, asymmetric thickening or nodules, and abnormal skin changes)
- Patients undergoing full sequence BMRI examination
- Through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant
Exclusion
- The breast had received radiotherapy, chemotherapy, biology and other treatments before BMRI.
- There are contraindications for breast-enhanced MRI examinations such as allergy to contrast agents.
- A prosthesis is implanted in the affected breast.
- Patients during lactation or pregnancy
Key Trial Info
Start Date :
February 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT05243121
Start Date
February 28 2022
End Date
September 30 2025
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking university people's hospital
Beijing, Beijing Municipality, China, 100044